MCID: INV004
MIFTS: 32

Invasive Bladder Transitional Cell Carcinoma

Categories: Cancer diseases, Nephrological diseases

Aliases & Classifications for Invasive Bladder Transitional Cell Carcinoma

MalaCards integrated aliases for Invasive Bladder Transitional Cell Carcinoma:

Name: Invasive Bladder Transitional Cell Carcinoma 12 15
Infiltrating Bladder Urothelial Carcinoma 72
Invasive Bladder Urothelial Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6477
NCIt 50 C27885
UMLS 72 C1334281

Summaries for Invasive Bladder Transitional Cell Carcinoma

MalaCards based summary : Invasive Bladder Transitional Cell Carcinoma, also known as infiltrating bladder urothelial carcinoma, is related to non-invasive bladder urothelial carcinoma and transitional cell carcinoma, and has symptoms including dysuria An important gene associated with Invasive Bladder Transitional Cell Carcinoma is NOTCH1 (Notch Receptor 1), and among its related pathways/superpathways are Gastric cancer and Glioma. The drugs Cisplatin and Pemetrexed have been mentioned in the context of this disorder. Affiliated tissues include prostate, and related phenotypes are hearing/vestibular/ear and renal/urinary system

Related Diseases for Invasive Bladder Transitional Cell Carcinoma

Graphical network of the top 20 diseases related to Invasive Bladder Transitional Cell Carcinoma:



Diseases related to Invasive Bladder Transitional Cell Carcinoma

Symptoms & Phenotypes for Invasive Bladder Transitional Cell Carcinoma

UMLS symptoms related to Invasive Bladder Transitional Cell Carcinoma:


dysuria

MGI Mouse Phenotypes related to Invasive Bladder Transitional Cell Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hearing/vestibular/ear MP:0005377 9.26 CDKN1A MSRB3 NOTCH1 TP53
2 renal/urinary system MP:0005367 8.92 CDKN1A HOXA13 NOTCH1 TP53

Drugs & Therapeutics for Invasive Bladder Transitional Cell Carcinoma

Drugs for Invasive Bladder Transitional Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 26)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 1, Phase 2 15663-27-1 84093 441203 2767
2
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556
3
leucovorin Approved Phase 2 58-05-9 143 6006
4
Gemcitabine Approved Phase 2 95058-81-4 60750
5
Methotrexate Approved Phase 1, Phase 2 1959-05-2, 59-05-2 126941
6
Vinblastine Approved Phase 1, Phase 2 865-21-4 241903 13342
7
Durvalumab Approved, Investigational Phase 1, Phase 2 1428935-60-7
8
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
9
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
10
Tremelimumab Investigational Phase 1, Phase 2 745013-59-6
11 Folic Acid Antagonists Phase 2
12 Vitamin B9 Phase 2
13 Nucleic Acid Synthesis Inhibitors Phase 2
14 Antibodies Phase 2
15 Folate Phase 2
16 Vitamin B Complex Phase 2
17 Antibodies, Monoclonal Phase 2
18 Immunoglobulins Phase 2
19 Immunologic Factors Phase 1, Phase 2
20 Anti-Infective Agents Phase 2
21 Immunosuppressive Agents Phase 2
22 Antimetabolites Phase 2
23 Antimetabolites, Antineoplastic Phase 2
24 Antiviral Agents Phase 2
25
Liposomal doxorubicin Phase 1, Phase 2 31703
26
Altretamine Approved Phase 1 645-05-6 2123

Interventional clinical trials:

(show all 11)
# Name Status NCT ID Phase Drugs
1 A Phase II Trial of Combination Cabazitaxel and Cisplatin Chemotherapy in the Neo-adjuvant Treatment of Transitional Cell Carcinoma of the Urinary Bladder Unknown status NCT01616875 Phase 2 Cabazitaxel + Cisplatin chemotherapy
2 A Phase II Trial to Evaluate Combination Therapy With Pemetrexed and Avelumab in Previously Treated Patients With MTAP-Deficient Advanced Urothelial Cancer Recruiting NCT03744793 Phase 2 Avelumab;Pemetrexed
3 A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients With Muscle-Invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations Recruiting NCT03609216 Phase 2 Gemcitabine Hydrochloride;Cisplatin
4 NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab (MEDI4736) and Tremelimumab in Muscle-invasive Urothelial Carcinoma Recruiting NCT03549715 Phase 1, Phase 2 Durvalumab;Tremelimumab;MVAC Protocol
5 A Randomized Phase II Trial Evaluating an Organ-conserving Strategy With Radiotherapy + CDDP + Gemcitabine vs Radiotherapy + CDDP in Muscle-infiltrative Bladder Cancer Recruiting NCT01495676 Phase 2
6 A Phase II Study of Radiation Therapy and Pembrolizumab in Patients With Localized Urothelial Bladder Cancer That Are Ineligible or Refusing Chemotherapy Withdrawn NCT03419130 Phase 2
7 A Pilot Study of Neoadjuvant sEphB4-HSA in Patients With Genitourinary Cancers Recruiting NCT02767921 Phase 1
8 A Phase I Study of Intravesical Talimogene Laherparepvec for Non-Muscle Invasive Transitional Cell Carcinoma Withdrawn NCT03430687 Phase 1
9 Prospective Study of Bladder-Preservation Chemo-Radiotherapy (Partial Bladder Hypo-fractionated Radiotherapy) for Patients With Muscle-Invasive Bladder Cancer Recruiting NCT02688348
10 Robot-Assisted Laparoscopic HIFU (High-Intensity Focused Ultrasound) of the Bladder Wall for Thermal Ablation of Muscle Invasive Cells of Bladder Tumors: Corroborating With Robot-Assisted Radical Cystectomy Withdrawn NCT03238664
11 Pilot Study of Gemcitabine and Cisplatin Plus AGS-003-BLD in Patients With Muscle-Invasive Bladder Cancer Undergoing Neoadjuvant Cisplatin-Based Chemotherapy Withdrawn NCT02944357 Cisplatin;Gemcitabine Hydrochloride

Search NIH Clinical Center for Invasive Bladder Transitional Cell Carcinoma

Genetic Tests for Invasive Bladder Transitional Cell Carcinoma

Anatomical Context for Invasive Bladder Transitional Cell Carcinoma

MalaCards organs/tissues related to Invasive Bladder Transitional Cell Carcinoma:

41
Prostate

Publications for Invasive Bladder Transitional Cell Carcinoma

Articles related to Invasive Bladder Transitional Cell Carcinoma:

(show all 36)
# Title Authors PMID Year
1
Identifying Potential Prognostic Markers for Muscle-Invasive Bladder Urothelial Carcinoma by Weighted Gene Co-Expression Network Analysis. 38
31011911 2019
2
Application of fluorescence in situ hybridization in the detection of bladder transitional-cell carcinoma: A multi-center clinical study based on Chinese population. 38
30775255 2019
3
IL‑23 concentration‑dependently regulates T24 cell proliferation, migration and invasion and is associated with prognosis in patients with bladder cancer. 38
30542702 2018
4
Clinical experience of MRI in two dogs with muscle-invasive transitional cell carcinoma of the urinary bladder. 38
27149892 2016
5
Relevance of prostate cancer in patients with synchronous invasive bladder urothelial carcinoma: a monocentric retrospective analysis. 38
25847902 2015
6
Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder. 38
26046361 2015
7
Impact of ABO blood type on outcomes in patients with primary nonmuscle invasive bladder cancer. 38
24333243 2014
8
Detection of specific chromosomal aberrations in urine using BCA-1 (oligo-CGH-array) enhances diagnostic sensitivity and predicts the aggressiveness of non-muscle-invasive bladder transitional cell carcinoma. 38
24196429 2014
9
Association of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder. 38
23994370 2014
10
Overexpression of RING box protein-1 (RBX1) associated with poor prognosis of non-muscle-invasive bladder transitional cell carcinoma. 38
23609182 2013
11
Abnormal expression of multiple proteins predicts cancer-specific mortality in patients with high-grade non-muscle-invasive bladder cancer treated with transurethral resection. 38
24649194 2013
12
Parallel proteomic analysis in muscle-invasive bladder transitional cell carcinoma and cancer-related stroma. 38
23479173 2013
13
Knockdown of regulator of cullins-1 (ROC1) expression induces bladder cancer cell cycle arrest at the G2 phase and senescence. 38
23667514 2013
14
Advanced transitional cell carcinoma of the bladder in a 16-year-old girl with Hinman syndrome. 38
22743257 2012
15
Single-cell sequencing analysis characterizes common and cell-lineage-specific mutations in a muscle-invasive bladder cancer. 38
23587365 2012
16
[Expression analysis of NOTCH1/HES1/PTEN signaling pathway in invasive bladder transitional cell carcinoma]. 38
22781569 2012
17
Efficacy of instillations with chemotherapy or immunotherapy following endoscopic resection for upper tract urothelial carcinoma. 38
22149433 2012
18
Screening and identification of specific markers for bladder transitional cell carcinoma from urine urothelial cells with suppressive subtractive hybridization and cDNA microarray. 38
21251473 2011
19
Long-term outcome of radical cystectomy in ESDR patients with bladder urothelial carcinoma. 38
21516473 2011
20
Overexpression of Eg5 predicts unfavorable prognosis in non-muscle invasive bladder urothelial carcinoma. 38
21449971 2011
21
Proteomics research on muscle-invasive bladder transitional cell carcinoma. 38
21645413 2011
22
[Evaluation of HER2 protein overexpression in non-muscle-invasive bladder cancer with emphasis on tumour grade and recurrence]. 38
21419519 2011
23
Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. 38
20939013 2010
24
D-type cyclins in superficial and muscle-invasive bladder urothelial carcinoma: correlation with clinicopathological data and prognostic significance. 38
20174823 2010
25
Loss of DeltaNp63alpha promotes invasion of urothelial carcinomas via N-cadherin/Src homology and collagen/extracellular signal-regulated kinase pathway. 38
19934319 2009
26
Downstaging and survival benefits of neoadjuvant radiotherapy before cystectomy for patients with invasive bladder carcinoma. 38
19363744 2009
27
Association of low expression of notch-1 and jagged-1 in human papillary bladder cancer and shorter survival. 38
18499162 2008
28
Characteristics of female non-muscle-invasive bladder cancer in Taiwan: association with upper tract urothelial carcinoma and end-stage renal disease. 38
18372011 2008
29
[Place of laparoscopic radical cystectomy in the treatment of invasive bladder urothelial carcinoma]. 38
18472066 2008
30
Behavior of urothelial carcinoma with respect to anatomical location. 38
17437794 2007
31
Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. 38
17222615 2007
32
Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group. 38
17011058 2006
33
[Radical cystectomy with sparing partial prostate for invasive bladder cancer]. 38
14558952 2003
34
Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma. 38
11696726 2001
35
The prognostic value of peripheral blood lymphocyte subsets in patients with bladder carcinoma treated using neoadjuvant M-VEC chemotherapy. 38
10571638 1999
36
Contemporary results of radical radiotherapy for bladder transitional cell carcinoma in a district general hospital with cancer-centre status. 38
10233566 1999

Variations for Invasive Bladder Transitional Cell Carcinoma

Expression for Invasive Bladder Transitional Cell Carcinoma

Search GEO for disease gene expression data for Invasive Bladder Transitional Cell Carcinoma.

Pathways for Invasive Bladder Transitional Cell Carcinoma

GO Terms for Invasive Bladder Transitional Cell Carcinoma

Biological processes related to Invasive Bladder Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.65 TP53 NOTCH1 CDKN1A
2 Ras protein signal transduction GO:0007265 9.46 TP53 CDKN1A
3 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.43 TP53 CDKN1A
4 animal organ regeneration GO:0031100 9.4 NOTCH1 CDKN1A
5 cellular response to ionizing radiation GO:0071479 9.37 TP53 CDKN1A
6 cell cycle arrest GO:0007050 9.33 TP53 NOTCH1 CDKN1A
7 intrinsic apoptotic signaling pathway GO:0097193 9.32 TP53 CDKN1A
8 positive regulation of reactive oxygen species metabolic process GO:2000379 9.26 TP53 CDKN1A
9 replicative senescence GO:0090399 8.96 TP53 CDKN1A
10 signal transduction by p53 class mediator GO:0072331 8.62 TP53 CDKN1A

Sources for Invasive Bladder Transitional Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....